Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan

264 patients scheduled for total hip arthroplasty were randomized to one of three groups: a group which received 15mg edoxaban daily, a group which received 30mg edoxaban daily, or a group which received 20mg of enoxaparin sodium twice daily. This was done to determine the safety, efficacy, and optimal dosage regimen of edoxaban as compared to enoxaparin in patients undergoing total hip arthroplasty. Factors such as the incidence of thromboembolic events, bleeding, and adverse drug reactions were evaluated over a 14 day postoperative period. The results demonstrated that edoxaban is a safe and efficacious alternative to enoxaparin sodium, and that a 30mg daily dose of edoxaban is appropriate.